ALG9

ALG9 alpha-1,2-mannosyltransferase, the group of Dolichyl D-mannosyl phosphate dependent mannosyltransferases

Basic information

Region (hg38): 11:111782195-111871581

Previous symbols: [ "DIBD1" ]

Links

ENSG00000086848NCBI:79796OMIM:606941HGNC:15672Uniprot:Q9H6U8AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autosomal dominant polycystic kidney disease (Moderate), mode of inheritance: AD
  • ALG9-congenital disorder of glycosylation (Strong), mode of inheritance: AR
  • ALG9-congenital disorder of glycosylation (Limited), mode of inheritance: AR
  • Gillessen-Kaesbach-Nishimura syndrome (Moderate), mode of inheritance: AR
  • ALG9-congenital disorder of glycosylation (Strong), mode of inheritance: AR
  • autosomal dominant polycystic kidney disease (Supportive), mode of inheritance: AD
  • ALG9-congenital disorder of glycosylation (Supportive), mode of inheritance: AR
  • ALG9-congenital disorder of glycosylation (Strong), mode of inheritance: AR
  • ALG9-congenital disorder of glycosylation (Moderate), mode of inheritance: AR
  • ALG9-associated autosomal dominant polycystic kidney disease (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Congenital disorder of glycosylation, type IlARHematologicAwareness of coagulopathies may be beneficial in terms of medical management, especially in situations such as surgeryBiochemical; Craniofacial; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Pulmonary; Renal15148656; 15945070; 19451548; 25966638
Hepatic-metabolized agents should be avoided

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ALG9 gene.

  • ALG9_congenital_disorder_of_glycosylation (210 variants)
  • Gillessen-Kaesbach-Nishimura_syndrome (72 variants)
  • not_provided (59 variants)
  • ALG9-related_disorder (33 variants)
  • not_specified (28 variants)
  • Inborn_genetic_diseases (18 variants)
  • Autosomal_dominant_polycystic_liver_disease (5 variants)
  • ALG9-associated_autosomal_dominant_polycystic_kidney_disease (3 variants)
  • Familial_cystic_renal_disease (2 variants)
  • Polycystic_kidney_disease,_adult_type (2 variants)
  • Congenital_disorder_of_glycosylation (1 variants)
  • Gillessen-Kaesbach-Nishimura_dysplasia (1 variants)
  • See_cases (1 variants)
  • Autosomal_dominant_polycystic_kidney_disease (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ALG9 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000024740.2. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
4
clinvar
49
clinvar
53
missense
2
clinvar
1
clinvar
101
clinvar
12
clinvar
3
clinvar
119
nonsense
5
clinvar
6
clinvar
2
clinvar
13
start loss
0
frameshift
5
clinvar
6
clinvar
11
splice donor/acceptor (+/-2bp)
8
clinvar
1
clinvar
9
Total 12 21 108 61 3

Highest pathogenic variant AF is 0.0000712557

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ALG9protein_codingprotein_codingENST00000531154 1189387
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.0006400.9991247760201247960.0000801
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.011902330.8140.00001202901
Missense in Polyphen6489.2510.717081112
Synonymous0.3668185.30.9500.00000433863
Loss of Function2.911026.00.3850.00000137308

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0002100.000209
Ashkenazi Jewish0.00009970.0000993
East Asian0.00005560.0000556
Finnish0.00009280.0000928
European (Non-Finnish)0.00007960.0000794
Middle Eastern0.00005560.0000556
South Asian0.00003270.0000327
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Catalyzes the transfer of mannose from Dol-P-Man to lipid-linked oligosaccharides. {ECO:0000269|PubMed:15148656, ECO:0000269|PubMed:15945070}.;
Disease
DISEASE: Congenital disorder of glycosylation 1L (CDG1L) [MIM:608776]: A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. {ECO:0000269|PubMed:15148656, ECO:0000269|PubMed:15945070}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Gillessen-Kaesbach-Nishimura syndrome (GIKANIS) [MIM:263210]: A rare autosomal recessive syndrome characterized by severe skeletal dysplasia, facial dysmorphic features, polycystic kidney disease and other visceral malformations. It may be lethal in utero or early in life. The skeletal features uniformly comprise a round pelvis, mesomelic shortening of the upper limbs and defective ossification of the cervical spine. {ECO:0000269|PubMed:25966638}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
N-Glycan biosynthesis - Homo sapiens (human);Post-translational protein modification;Metabolism of proteins;Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein;Asparagine N-linked glycosylation (Consensus)

Recessive Scores

pRec
0.216

Intolerance Scores

loftool
0.881
rvis_EVS
0.51
rvis_percentile_EVS
80.1

Haploinsufficiency Scores

pHI
0.504
hipred
N
hipred_score
0.488
ghis
0.537

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.231

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Alg9
Phenotype

Gene ontology

Biological process
dolichol-linked oligosaccharide biosynthetic process;mannosylation
Cellular component
endoplasmic reticulum;endoplasmic reticulum membrane;membrane;integral component of membrane
Molecular function
alpha-1,2-mannosyltransferase activity;mannosyltransferase activity;dol-P-Man:Man(8)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase activity;dol-P-Man:Man(6)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase activity